No Detail Found!

Cardiac troponin-I, A biomarker for predicting COVID-induced myocardial damage prognosis

Author(s)
Abdul Rehman Department of Chemical Pathology, Karachi Institute of Medical Sciences, Combined Military Hospital,Malir, Karachi,Pakistan
Shagufta Yousuf Department of Chemical Pathology, Karachi Institute of Medical Sciences, Combined Military Hospital,Malir, Karachi,Pakistan
Ghulam Rasool Maken Department of Medicine, Karachi Institute of Medical Sciences, Combined Military Hospital, Malir, Karachi, Pakistan
Syed Rehan Asghar Naqvi Department of Chemical Pathology, Karachi Institute of Medical Sciences, Combined Military Hospital,Malir, Karachi,Pakistan
Ghulam Murtaza Department of Pathology, PNS Rahat Hospital, Karachi, Pakistan
Abeera Ahmad Department of Pathology, Karachi Institute of Medical Sciences, Combined Military Hospital, Malir, Karachi, Pakistan
Abstract
Objective: To analyse the utility of cardiac Troponin-I as a prognostic marker in COVID-19-induced myocardial injury. Study Design: A descriptive study. Place and Duration of the Study: COVID Intensive Therapeutic Unit (ITC) and Pathology Department, Combined Military Hospital (CMH), Malir, Karachi, from September 2021 to February 2022. Methodology: Patients with chest pain, who tested positive for COVID-19 by real-time PCR, were inducted. Blood samples were screened for in ammatory and cardiac biomarkers. The levels of cardiac Troponin I (cTn-I) were categorised as normal (99th percentile = d0.01 ng/ml), raised (5 times the 99th percentile = >0.01 ng/ml), and markedly raised (>10 times the 99th percentile = >10 ng/ml) based on serial monitoring over a duration of 6-8 hours. Results: Out of a total of 104 patients, the mean age was 48 ± 15.94 years; 78 (75%) were males and 26 (25%) were females. The mean levels of cardiac Troponin I (cTn-I) were 1.91 ng/ml, C-reactive protein (CRP) was 85 mg/l, Interleukin-6 (IL-6) was 43.3 ng/ml, Procalcitonin (PCT) was 1.40 ng/ml, Creatinine Kinase (CK) was 203 U/l, CK MB was 31 U/l, and Ferritin was 471 ng/ml. Forty-four (42.4%) had normal cTn-I levels, 38 (36.5%) had raised levels, and 22 (21.1%) had markedly raised levels. A persistent rising pattern of cTn-I with a maximum rise up to 30 ng/ml was observed in 16 patients (15.3%) labelled as myocarditis, while only 8 (7.6%) showed a rise-fall pattern. Cardiac Tn-I and CRP were signi cantly higher in patients with myocarditis (p <0.01). Six out of 104 patients (5.7%) died due to COVID- induced myocardial injury all having raised cTn-I. Conclusion: Cardiac Troponin-I is an e ective biomarker for measuring myocardial injury in COVID-19 patients and can be an independent predictor to assess for severity of cardiac injury than other in ammatory markers in COVID-19.
Publication Details
Page(s) 498-503
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 5, Year: 2023

Request the full text from PASTIC

Keywords
Prognosis, COVID-19, COVID-19, Myocardial injury, Cardiac Troponin I, In ammatory markers
0

Citations

0

Downloads

61

Views